The Children's Oncology Group (COG) is the largest childhood cancer research organization in the world encompassing 224 pediatric cancer programs with a mission to cure and prevent childhood and adolescent cancer through scientific discovery and compassionate care. GOG was formed from the merger of four legacy pediatric cooperative groups in 2000 and the COG Community Clinical Oncology Program (CCOP) Research Base was funded in 2002. The proposed COG NCORP Research Base will support 25 Community Sites and 12 Minority/Underserved Community Sites and is the only research base exclusively dedicated to children and adolescents. It will encompass the near totality of U.S. community pediatric oncology. The COG NCORP Research Base will provide access to state-of-the-art cancer treatment at community sites and nationally promote pediatric research in cancer prevention and control, post-treatment surveillance/survivorship, and cancer care delivery. COG trials and laboratory research will translate into more effective treatments with reduced side effects. Community-based pediatric oncologists and other health professionals are pivotal to COG's research mission. NCORP sites provide a means to evaluate advanced treatments administered in community settings. The COG makes available to NCORP sites current treatment protocols with access to investigational agents and special centralized reference laboratories, continuing training and support for NCORP personnel, quality assurance infrastructure, data management and statistical support, thus promoting scientific discovery and high quality cancer care for young persons. The COG is uniquely positioned to elucidate the impact of different health care delivery systems and characteristics on cancer outcomes and identify determinants of poorer outcomes in certain race/ethnic and underserved groups such as adolescents and young adults. Such research will improve outcomes by eliminating disparities and improving efficiencies for the delivery of cancer therapy and follow-up care in young persons.
The Children's Oncology Group (COG) is the world's largest organization devoted exclusively to childhood and adolescent cancer research. Over 200 leading children's hospitals, universities, and cancer centers across North America participate in COG research, which is focused on developing better treatments and improved quality of life for all children with cancer.
|Dupuis, L Lee; Kelly, Kara M; Krischer, Jeffrey P et al. (2018) Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer 124:1188-1196|
|Zheng, Daniel J; Lu, Xiaomin; Schore, Reuven J et al. (2018) Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer 124:571-579|
|Knight, Kristin R; Chen, Lu; Freyer, David et al. (2017) Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Clin Oncol 35:440-445|
|Haase, Joan E; Kintner, Eileen K; Robb, Sheri L et al. (2017) The Resilience in Illness Model Part 2: Confirmatory Evaluation in Adolescents and Young Adults With Cancer. Cancer Nurs 40:454-463|
|Carlos, Ruth C; Sicks, JoRean D; Chang, George J et al. (2017) Capacity for Cancer Care Delivery Research in National Cancer Institute Community Oncology Research Program Community Practices: Availability of Radiology and Primary Care Research Partners. J Am Coll Radiol 14:1530-1537|
|Loeffen, E A H; Kremer, L C M; Mulder, R L et al. (2017) The importance of evidence-based supportive care practice guidelines in childhood cancer-a plea for their development and implementation. Support Care Cancer 25:1121-1125|
|Freyer, David R; Chen, Lu; Krailo, Mark D et al. (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:63-74|
|Viola, Adrienne; Balsamo, Lyn; Neglia, Joseph P et al. (2017) The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment. J Pediatr Hematol Oncol 39:174-178|
|Liu, C; Yang, W; Pei, D et al. (2017) Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther 101:373-381|
|Hendricks-Ferguson, Verna L; Barnes, Yvonne J; Cherven, Brooke et al. (2017) Stories and Music for Adolescent/Young Adult Resilience During Transplant Partnerships: Strategies to Support Academic-Clinical Nurse Collaborations in Behavioral Intervention Studies. Clin Nurse Spec 31:195-200|
Showing the most recent 10 out of 50 publications